This company listing is no longer active
NeuBase Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
NeuBase Therapeutics has a total shareholder equity of $14.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.5M and $7.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$13.85m |
| Equity | US$14.45m |
| Total liabilities | US$7.01m |
| Total assets | US$21.46m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: O7P's short term assets ($14.2M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: O7P's short term assets ($14.2M) exceed its long term liabilities ($5.1M).
Debt to Equity History and Analysis
Debt Level: O7P is debt free.
Reducing Debt: O7P had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if O7P has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if O7P has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.